|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
654300700[A15253441]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2008.11.01)(ÇöÀç¾à°¡)
\179 ¿ø/1Á¤(2005.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| ÁÖ¼ººÐÄÚµå |
218001ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¿ø¹ß¼º °íÁöÇ÷Áõ : °íÄÝ·¹½ºÅ×·ÑÇüÁõ(llaÇü), °íÄÝ·¹½ºÅ×·ÑÇüÁõ°ú °íÆ®¸®±Û¸®¼¼¶óÀ̵åÇ÷ÁõÀÇ º¹ÇÕÇü(llbÇü)
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:218001ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¼ºÀÎ 1ȸ 2Á¤¾¿, 1ÀÏ 2ȸ ¾ÆÄ§, Àú³á ½Ä»ç¿Í ÇÔ²² °æ±¸ Åõ¿©ÇϵÇ, ¹Ýµå½Ã ½ÄÀÌ¿ä¹ýÀ» º´ÇàÇÕ´Ï´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÕ´Ï´Ù.
|
| ±Ý±â |
- ÀÌ ¾à¿¡ °ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
- ÁßÁõ ½É½Ç¼º ºÎÁ¤¸Æ(´Ù¿ø¼º ½É½Ç¼º ±â¿Ü¼öÃàÀÇ ´Ù¹ß) ȯÀÚ[´õ¿í ÁßÁõÀÇ ½É½Ç¼º ºÎÁ¤¸ÆÀÎ Å丣»çµå µå Æ÷ÀÎÆ®(torsades de pointes)°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.]
- ½É±Ù¼Õ»ó ȯÀÚ
- ¿øÀÎºÒ¸í ¶Ç´Â ½ÉÇ÷°ü ¿øÀÎÀÇ ½Ç½Å ȯÀÚ
- ºñÁ¤»óÀûÀ¸·Î QT°£°ÝÀÌ ¿¬ÀåµÈ ȯÀÚ
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ, ¼öÀ¯ºÎ
- ±Þ ¸¸¼º °£¿° ȯÀÚ
- ¿°Áõ¼º ÀåÁúȯ ȯÀÚ
- °£³» °£¿Ü ´ãÁó¿ïü ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ½É±Ù°æ»öÀÇ ÃʱâÁõ¼¼ ¹× ¿ïÇ÷¼º ½ÉºÎÀü ȯÀÚ(½É½Ç¼º ºÎÁ¤¸ÆÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
- ½É½Ç¼º ºÎÁ¤¸Æ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- ¼øÈ¯±â°è :
µå¹°°Ô ÇöÀúÇÑ QT°£°Ý¿¬Àå¿¡ ¼ö¹ÝÇÏ¿© ½É½Ç¼º ºÎÁ¤¸Æ[Å丣»çµå µå Æ÷ÀÎÆ®(torsade de point), ½É½Çºó¸Æ, ½É½Ç¼¼µ¿], ½Ç½ÅÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
Á¤½Å½Å°æ°è : ¸»ÃʽŰ濰, ¶§¶§·Î ¾îÁö·¯¿ò, µÎÅë, °¨°¢ÀÌ»ó, ºÒ¸é, À̸íÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°ú¹ÎÁõ : ¶§¶§·Î ¹ßÁø, °¡·Á¿ò, Ç÷°ü½Å°æ¼º ºÎÁ¾ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
ÇǺΠ: ¹Ý»óÃâÇ÷, Á¡»óÃâÇ÷, ´ÙÇÑ, ÃëÇÑ(ö«ùÒ) µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Ç÷¾×°è : ¶§¶§·Î È£»ê±¸Áõ´Ù, ºóÇ÷(Çì¸ð±Û·Îºó, Ç츶ÅäÅ©¸´Æ®Ä¡ °¨¼Ò), Ç÷¼ÒÆÇ°¨¼Ò, ¹éÇ÷±¸°¨¼Ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ¼ÒȰüÃâÇ÷, ¶§¶§·Î ¼³»ç, ¹±Àº º¯, ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø, º¹Åë, °¡½¿¾²¸², ½É¿ÍºÎµ¿Åë, º¹ºÎÆØ¸¸°¨, ¼ÒȺҷ® µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£Àå : ¶§¶§·Î ALT, AST, ALP, LDH, ºô¸®·çºóÄ¡ÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
½ÅÀå : ¶§¶§·Î BUN»ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°ñ°Ý±Ù°è : ¶§¶§·Î ±ÙÀ°Åë, ¹«·Â°¨, Ç÷Áß ¶Ç´Â ¿äÁß ¹Ì¿À±Û·Îºó »ó½Â, CPK»ó½ÂÀ» Ư¡À¸·Î Çϴ Ⱦ¹®±ÙÀ¶ÇØÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
ºñ´¢±â°è : ¹ß±âºÎÀü, ¾ß´¢ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
´« : °á¸·¿°, ´«¹°, ½Ã·ÂºÒ¼±¸íÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
³»ºÐºñ°è : ´ÙÀý¼º °©»ó¼±Á¾ÀÇ ºñ´ë°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ƯÀÌüÁú : Åõ¿©Ãʱ⿡ ¾îÁö·¯¿ò, ½É°èÇ×Áø, ½Ç½Å, ±¸¿ª, ±¸Åä, ÈäÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ : ¶§¶§·Î ¿ä»ê»ó½Â, °øº¹½Ã Ç÷´ç»ó½Â, µå¹°°Ô ±Çۨ, ¹Ì°¢ Èİ¢ °¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
- ÀÌ ¾à°ú Å׸£Æä³ªµò, ¾Æ½ºÅ×¹ÌÁ¹À» º´¿ëÅõ¿©Çϸé QT ¿¬Àå, ½É½Ç¼º ºÎÁ¤¸ÆÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿© ÇÏÁö ¾Ê´Â´Ù.
- QT°£°ÝÀ» ¿¬ÀåÇÏ´Â ¾à¹°(»ïȯ°è Ç׿ì¿ïÁ¦, Æä³ëÄ¡¾ÆÁø°è ¾à¹°, Class ¥°, ¥² ºÎÁ¤¸Æ¿ëÁ¦)°ú º´¿ëÅõ¿©½Ã ÁßÁõ ºÎÁ¤¸ÆÀÇ À§Ç輺ÀÌ Áõ°¡µÉ ¼ö ÀÖ´Ù.
- °æ±¸¿ë Ç÷´ç°ÇÏÁ¦³ª Ç×ÀÀ°íÁ¦´Â Ç÷û ÄÝ·¹½ºÅ×·Ñ¿¡ ´ëÇÑ ÀÌ ¾àÀÇ È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê´Â´Ù.
- Ŭ·ÎÇǺ극ÀÌÆ®¿Í º´¿ëÅõ¿©½Ã HDL-ÄÝ·¹½ºÅ×·ÑÀÇ ÇöÀúÇÑ ÀúÇϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
- »çÀÌŬ·Î½ºÆ÷¸°°ú º´¿ëÅõ¿©½Ã »çÀÌŬ·Î½ºÆ÷¸°ÀÇ Ç÷Áß³óµµ°¡ ÀúÇ쵃 ¼ö ÀÖ´Ù.
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: PROBUCOLLORELCO (PROBUCOL)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Probucol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis.
|
| Pharmacology |
Probucol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Probucol is a powerful antioxidant drug normally used to prevent vascular disease caused by the free radicals in the body.
|
| Half-life |
Probucol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.
|
| Absorption |
Probucol¿¡ ´ëÇÑ Absorption Á¤º¸ Absorption from the gastrointestinal tract is limited and variable (about 7%).
|
| Pharmacokinetics |
ProbucolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ¸Å¿ì ¼¼È÷, ¼Ò·® Èí¼öµÈ´Ù. (10% ÀÌÇÏ)
- ¼Ò½Ç ¹Ý°¨±â : 20ÀÏ
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : Áö¼ÓÀû ¹Ýº¹ Åõ¿©¸¦ ½ÃÀÛÇÑÁö ¡3°³¿ù ÈÄ
- ¼Ò½Ç : ÁÖ·Î ´ãÁóÀ» ÅëÇØ º¯À¸·Î ¹è¼³µÈ´Ù.
|
| Biotransformation |
Probucol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Drug Interactions |
Probucol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Cyclosporine Probucol decreases the effect of cyclosporine
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Probucol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food. Food increases availability.
|
| Description |
Probucol¿¡ ´ëÇÑ Description Á¤º¸ A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
|
| Dosage Form |
Probucol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet OralTablet Oral
|
| Drug Category |
Probucol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anticholesteremic AgentsAntioxidants
|
| Smiles String Canonical |
Probucol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
|
| Smiles String Isomeric |
Probucol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
|
| InChI Identifier |
Probucol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
|
| Chemical IUPAC Name |
Probucol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|